Top-Rated StocksTop-RatedNASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free JAZZ Stock Alerts $120.42 -0.09 (-0.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$120.03▼$121.5350-Day Range$115.79▼$132.7752-Week Range$111.25▼$147.98Volume403,590 shsAverage Volume629,391 shsMarket Capitalization$7.59 billionP/E Ratio19.68Dividend YieldN/APrice Target$195.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Jazz Pharmaceuticals alerts: Email Address Jazz Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside62.0% Upside$195.08 Price TargetShort InterestBearish4.60% of Float Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.29Based on 22 Articles This WeekInsider TradingAcquiring Shares$1.44 M Bought Last QuarterProj. Earnings Growth15.17%From $16.15 to $18.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.97 out of 5 starsMedical Sector13th out of 938 stocksPharmaceutical Preparations Industry7th out of 424 stocks 4.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $195.08, Jazz Pharmaceuticals has a forecasted upside of 62.0% from its current price of $120.42.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.60% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 15.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 1.8 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 44 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -2% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have bought 519.89% more of their company's stock than they have sold. Specifically, they have bought $1,435,800.00 in company stock and sold $231,623.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 15.17% in the coming year, from $16.15 to $18.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 19.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 147.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 19.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 275.57.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.64. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More JAZZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAZZ Stock News HeadlinesMarch 11, 2024 | insidertrades.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells $231,623.04 in StockMarch 28, 2024 | finanznachrichten.deJazz Pharmaceuticals: Cancer and the Combination ApproachMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 28, 2024 | finance.yahoo.comCancer and the Combination ApproachMarch 26, 2024 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $190.00 at JPMorgan Chase & Co.March 25, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Jazz Pharmaceuticals plc Lowered by Zacks Research (NASDAQ:JAZZ)March 23, 2024 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Receives "Overweight" Rating from Cantor FitzgeraldMarch 23, 2024 | americanbankingnews.comJazz Pharmaceuticals plc Expected to Earn Q4 2024 Earnings of $4.17 Per Share (NASDAQ:JAZZ)March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 21, 2024 | msn.comBiotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & MoreMarch 21, 2024 | markets.businessinsider.comOptimistic Outlook on Jazz Pharmaceuticals’ Zanidatamab Across Multiple Cancer Types: A Buy Rating AnalysisMarch 21, 2024 | americanbankingnews.comPiper Sandler Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $188.00March 21, 2024 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Earns Buy Rating from Needham & Company LLCMarch 21, 2024 | americanbankingnews.comTruist Financial Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Jazz Pharmaceuticals on Strong Zanidatamab Revenue Prospects and Clinical MilestonesMarch 20, 2024 | markets.businessinsider.comThe Analyst Landscape: 12 Takes On Jazz PharmaceuticalsMarch 20, 2024 | finance.yahoo.comJazz Pharmaceuticals Celebrates International Women’s DayMarch 19, 2024 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Given New $230.00 Price Target at Stifel NicolausMarch 16, 2024 | finance.yahoo.comJAZZ Apr 2024 110.000 putMarch 14, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To KnowMarch 14, 2024 | finance.yahoo.comUnlocking Jazz Pharmaceuticals' Potential: A Roadmap for GrowthMarch 14, 2024 | finance.yahoo.comExploring How Jazz Pharmaceuticals Honored U.S. Black History MonthMarch 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 12, 2024 | msn.comTime Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD UsersMarch 12, 2024 | prnewswire.comJazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024March 12, 2024 | finance.yahoo.comJazz Pharmaceuticals (NASDAQ:JAZZ) shareholders have endured a 32% loss from investing in the stock three years agoMarch 12, 2024 | markets.businessinsider.comStrong Buy Rating for AnaptysBio Based on Promising Pipeline and Financial HealthSee More Headlines Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Target$195.08 High Stock Price Target$230.00 Low Stock Price Target$131.00 Potential Upside/Downside+62.0%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$6.12 Trailing P/E Ratio19.68 Forward P/E Ratio7.46 P/E Growth1.64Net Income$414.83 million Net Margins10.82% Pretax Margin7.77% Return on Equity31.27% Return on Assets9.81% Debt Debt-to-Equity Ratio1.37 Current Ratio2.24 Quick Ratio1.85 Sales & Book Value Annual Sales$3.83 billion Price / Sales1.98 Cash Flow$28.40 per share Price / Cash Flow4.24 Book Value$59.36 per share Price / Book2.03Miscellaneous Outstanding Shares63,000,000Free Float60,228,000Market Cap$7.59 billion OptionableOptionable Beta0.59 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Bruce C. Cozadd (Age 60)Co-Founder, Chairman & CEO Comp: $2.45MMs. Reneé D. Galá (Age 52)President & COO Comp: $1.13MMr. Daniel N. Swisher Jr. (Age 61)Non-Executive Employee Comp: $1.47MDr. Robert Iannone M.D. (Age 57)Executive VP and Global Head of Research & Development Comp: $1.08MMr. Philip L. JohnsonExecutive VP & CFOMs. Patricia Carr (Age 52)Senior VP & Chief Accounting Officer Ms. Andrea N. Flynn Ph.D.VP & Head of Investor RelationsMs. Neena M. Patil J.D. (Age 48)Executive VP & Chief Legal Officer Comp: $331.61kDr. George Christopher Eliades Ph.D. (Age 53)Senior VP of Corporate Development & Chief Transformation Officer Ms. Heidi Manna (Age 53)Senior VP & Chief People Officer More ExecutivesKey CompetitorsPerrigoNYSE:PRGOMirati TherapeuticsNASDAQ:MRTXMyoKardiaNASDAQ:MYOKCorcept TherapeuticsNASDAQ:CORTCytokineticsNASDAQ:CYTKView All CompetitorsInsiders & InstitutionsNewbridge Financial Services Group Inc.Bought 336 shares on 3/28/2024Ownership: 0.001%HighPoint Advisor Group LLCBought 1,991 shares on 3/26/2024Ownership: 0.003%PNC Financial Services Group Inc.Sold 1,154 shares on 3/22/2024Ownership: 0.006%Vanguard Group Inc.Sold 15,305 shares on 3/11/2024Ownership: 10.101%Patricia CarrSold 1,936 sharesTotal: $231,623.04 ($119.64/share)View All Insider TransactionsView All Institutional Transactions JAZZ Stock Analysis - Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks. What is Jazz Pharmaceuticals' stock price target for 2024? 13 equities research analysts have issued 1 year price targets for Jazz Pharmaceuticals' shares. Their JAZZ share price targets range from $131.00 to $230.00. On average, they anticipate the company's stock price to reach $195.08 in the next year. This suggests a possible upside of 62.0% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts. How have JAZZ shares performed in 2024? Jazz Pharmaceuticals' stock was trading at $123.00 on January 1st, 2024. Since then, JAZZ shares have decreased by 2.1% and is now trading at $120.42. View the best growth stocks for 2024 here. Are investors shorting Jazz Pharmaceuticals? Jazz Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,770,000 shares, an increase of 15.9% from the February 29th total of 2,390,000 shares. Based on an average daily trading volume, of 637,100 shares, the days-to-cover ratio is currently 4.3 days. Approximately 4.6% of the shares of the company are sold short. View Jazz Pharmaceuticals' Short Interest. When is Jazz Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our JAZZ earnings forecast. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.44 by $0.04. The specialty pharmaceutical company earned $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a trailing twelve-month return on equity of 31.27%. What ETFs hold Jazz Pharmaceuticals' stock? ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE), Amplify Seymour Cannabis ETF (CNBS), AdvisorShares Pure Cannabis ETF (YOLO), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Pharmaceutical ETF (PPH), Invesco Pharmaceuticals ETF (PJP), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of 18.150-19.350 for the period, compared to the consensus earnings per share estimate of 19.940. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion. What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.11%), Vanguard Group Inc. (10.10%), LSV Asset Management (3.72%), Wellington Management Group LLP (2.05%), Polaris Capital Management LLC (2.01%) and Pacer Advisors Inc. (1.63%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More This page (NASDAQ:JAZZ) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.